Question-and-Answer Session
Operator
(Operator Instructions) Your first question comes from the line of Rich Silver of Barclays Capital.
Rich Silver - Barclays Capital
Hey Larry.
Larry Olanoff
Good morning.
Rich Silver - Barclays Capital
How are you?
Larry Olanoff
Good. Thank you.
Rich Silver - Barclays Capital
Just a question on the SG&A number for the year; is that still, even including the Daxas, is that still unchanged?
Larry Olanoff
I’ll let Frank comment on that, and then I’ll comment afterwards.
Frank Perier
What we’ve indicated is, that we have some incremental investments related to Daxas that was not planned for, but in total, we should be fairly close on total SG&A.
Rich Silver - Barclays Capital
Okay. Then in terms of the SSRI market growth, and Lexapro market share, are those still unchanged from previous expectations?
Frank Perier
We’re really not updating guidance on line-by-line items Rich. We’ve really just indicated that overall, our $4.1 billion of total revenues, the business remains on track to achieve that.
Rich Silver - Barclays Capital
Then on the Daxas launch, any plans to hire additional reps?
Larry Olanoff
At this time we have no plans to hire any additional reps to support the Daxas launch.
Rich Silver - Barclays Capital
Okay, and then on Bystolic and CHS, can you elaborate on what plans you have for that, assuming you gain the approval?
Larry Olanoff
We would plan to launch that product opportunity in the spring. If we gain the approval, we have an action date of March for that indication, and we’re preparing for that event as we speak now.
Rich Silver - Barclays Capital
Okay, thanks very much.
Operator
Your next question comes from the line of Corey Davis of Jefferies.
Corey Davis - Jefferies & Co.
Thanks very much, just two questions. The first, as it relates to Daxas, there’s FDA adcom coming up for Spiriva on November 19. I believe seeking the same claim is a reduction in exacerbation, so I’m not asking what you think the outcome for them would be, but do you think there are things we can learn about the FDA’s disposition on this indication and the studies that need to be done as being predictive for what the outcome for Daxas will be?
Larry Olanoff
Thanks Corey for the question. I think it will be very useful, and we plan to attend that meeting and listen into what is being discussed. My understanding is that the consideration for the exacerbation change will be based on the outlet trial, which as everyone knows is a very large trial.
- To read the full transcript on Seeking Alpha, click here »
